Ph.D., University of Colorado, 1983.
Postdoctoral Fellow, Harvard University, Cancer Biology.
Dr. Overbaugh's laboratory has a long-standing interest in understanding the mechanisms of HIV transmission and pathogenesis. A major hypothesis for the studies in her lab is that the variants of HIV-1 that are transmitted are a selected subset of all the viruses that evolve during the course of infection. Thus, an overarching goal of Dr. Overbaugh's research is to determine whether some variants are more transmissible and others are more pathogenic in the host and to define the mechanisms underlying these differences. Her lab has shown that there is a genetic bottleneck in the sequences that are transmitted, leading to selection of just one or a few HIV variants in a new host. Her lab's studies have shown that people already infected by HIV can become re-infected/superinfected with HIV from another source partner. Her laboratory is exploring the immune responses in individuals who become superinfected to determine if they have deficits in immunity that may explain their susceptibility to re-infection, which has implication for defining immune correlates of vaccine protection. Her lab is exploring similar question in the context of mother-infant transmission, where the infant is infected in the presence of maternal HIV-specific antibodies.
Much of the HIV research in the lab is focused on populations in Africa because this is where the AIDS epidemic is most severe. Studies include analyses of antiretroviral drug resistance, which has become increasingly important as HIV treatments become available in Africa. The laboratory is part of a larger team, comprising researchers in both Seattle and Kenya (The Nairobi HIV/STD Project), that is studying the molecular epidemiology of HIV transmission. The project is also examining the efficacy of various intervention strategies to limit the spread of HIV, particularly those that may be practical to implement in Africa and other parts of the developing world.
Dr. Overbaugh has served as Chair of the NIH study section on HIV Molecular Biology (1998-2000), and as a member of various NIH review panels. She has served as a member of the NIH Office of AIDS Research Advisory Council and as an Editor for the Journal of Virology.
Honors and Awards
2011, Fellow, American Academy of Microbiology
2010, MERIT Award, National Institutes of Health (NIH), Early & Reinfection in High Risk Women
2008, McDougall Mentoring Award, FHCRC
2007, Women & Minority Faculty Medicine Mentoring Award, University of Washington School of Medicine
1999-2009, MERIT Award, National Institutes of Health (NIH), Early Infection in Women Exposed Mucosally to HIV-1
1999-2004, Elizabeth Glaser Scientist, Pediatric AIDS Foundation
1993-1998, Scholar, Leukemia Society of America
1994-1998, Associate Professor, University of Washington, School of Medicine, Microbiology
Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.. PLoS pathogens. 13(1):e1006148.. 2017.
Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.. AIDS (London, England). 30(15):2303-2313.. 2016.
Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children.. AIDS (London, England). 30(18):2835-2843.. 2016.
Vertical Cytomegalovirus Transmission From HIV-Infected Women Randomized to Formula-Feed or Breastfeed Their Infants.. The Journal of infectious diseases. 213(6):992-998.. 2016.
HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.. Cell. 166(1):77-87.. 2016.
Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-α Resistance.. PLoS pathogens. 12(7):e1005727.. 2016.
Cross-subtype detection of HIV-1 using reverse transcription and recombinase polymerase amplification.. Journal of virological methods.. 2016.
Genital Shedding of Resistant Human Immunodeficiency Virus-1 Among Women Diagnosed With Treatment Failure by Clinical and Immunologic Monitoring.. Open forum infectious diseases. 3(1):ofw019.. 2016.
Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors that Affect Neutralization Sensitivity.. Journal of virology. 90(2):636-649.. 2016.
Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate.. Journal of acquired immune deficiency syndromes (1999). 71(4):359-66.. 2016.
HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics.. AIDS (London, England). 29(15):2025-33.. 2015.
A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. AIDS (London, England). 29(17):2279–2286.. 2015.
HIV transmission biology: translation for HIV prevention.. AIDS (London, England). 29(17):2219-2227.. 2015.
Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.. AIDS research and human retroviruses. 31(3):288-92.. 2015.
Development of SHIVs with circulating, transmitted HIV-1 variants.. Journal of medical primatology.. 2015.
Identification of owl monkey CD4 receptors broadly compatible with early-stage HIV-1 isolates.. Journal of virology. 89(16):8611-22.. 2015.
Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012.. AIDS (London, England). 29(9):1077-85.. 2015.
HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science (New York, N.Y.). 349(6244). 2015.
FCGR2A and FCGR3A Genotypes in Human Immunodeficiency Virus Mother-to-Child Transmission.. Open forum infectious diseases. 2(4):ofv149.. 2015.
Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.. AIDS research and human retroviruses. 31(8):783-91.. 2015.